Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain
tumor. Patients with GBM often have poor prognoses, with a median survival of∼ 15 months …

Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex
system, which in addition to cancer cells, consists of various resident brain and immune cells …

Glioblastoma (GBM) is a primary tumor of the brain defined by its uniform lethality and
resistance to conventional therapies. There have been considerable efforts to untangle the …

Patients with high ALDH1A3-expressing glioblastoma (ALDH1A3 hi GBM) show limited
benefit from postoperative chemoradiotherapy. Understanding the mechanisms underlying …

Glioblastoma is a primary malignant brain tumor with a median survival under 2 years. The
poor prognosis glioblastoma caries is largely due to cellular invasion, which enables escape …

Cancer cells rewire their metabolism to survive during cancer progression. In this context,
tumour metabolic heterogeneity arises and develops in response to diverse environmental …

Simple Summary Glioblastoma multiforme is a brain tumor with a very unfavorable
prognosis, where the vast majority of patients do not survive a year after diagnosis. One line …

Glioblastoma (GBM), the most aggressive and lethal brain cancer, is detected only in the
advanced stage, resulting in a median survival rate of 15 months. Therefore, there is an …

Background Glioblastoma (GBM) is the most common primary brain tumor with a dismal
prognosis. The inherent cellular diversity and interactions within tumor microenvironments …

Tumor metabolism is emerging as a potential target for cancer therapies. This new approach
holds particular promise for the treatment of glioblastoma, a highly lethal brain tumor that is …